Business context and reporting period
The supplied filing is a quarterly report for Marika Inc., a Nevada development-stage company formed on May 24, 2013 to pursue online errand and concierge services. It reports the quarter and six months ended December 31, 2013; financial statements are unaudited. The filing states the company had no business operations and no revenue. It was signed May 14, 2014.
Entity discrepancy: The request metadata identifies Palvella Therapeutics, Inc., but the filing itself identifies Marika Inc. The summary below reflects the supplied filing.
Financial results and position
| Metric | Three months ended Dec. 31, 2013 | Six months ended Dec. 31, 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $2,198 | $7,960 |
| Net loss | $2,198 | $7,960 |
| Net loss per share | $0.00, rounded | $0.00, rounded |
| Cash used in operating activities | $948 | $6,710 |
| Cash provided by financing activities | $1,600 | $1,600 |
At December 31, 2013, cash and total assets were $90, down from $5,200 at June 30, 2013. Current liabilities were $3,324, comprising $1,250 of accrued expenses and a $2,074 unsecured, non-interest-bearing director loan due on demand. Stockholders’ deficit was $3,234, versus equity of $4,726 at June 30. The company reported no investing cash flows and no interest or income taxes paid. No margins are meaningful because there was no revenue.
Since inception, financing provided $6,800: $5,000 from issuing 5,000,000 shares and $1,800 in director loans. The filing reports 5,000,000 shares outstanding.
Changes, outlook, and risks
- Compared with June 30, 2013, cash fell by $5,110, liabilities rose by $2,850, and equity of $4,726 became a deficit of $3,234. The company was newly formed, so the filing provides no prior-year comparable operating results.
- Management says operations will depend on additional capital, expected principally from equity or debt securities and potentially director loans. It says funds are expected to cover operations for the next three months, but additional funding will be required within twelve months; no financing arrangements are in place.
- The filing warns that financing may not be available on acceptable terms or at all, and equity or convertible debt issuance could dilute shareholders or have senior rights. Planned spending may include inventory, startup development, and marketing.
- The auditor’s review report included an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern. Management likewise states there is no assurance of financial viability.
- Management concluded disclosure controls and procedures were not effective as of December 31, 2013. It reported no material change in internal control over financial reporting during the quarter.
- No material subsequent events, legal proceedings, or material off-balance-sheet arrangements were reported.
Important facts for investors to verify
- Confirm the intended issuer: the request names Palvella Therapeutics, Inc., whereas the supplied 10-Q is for Marika Inc.
- Reconcile the reported quarterly loss: the statements show $2,198, while MD&A states $2,162; the expense breakdown lists $36 of operating expenses and $2,162 of professional fees.
- Verify cash-flow disclosures: the statement reports six-month operating cash use of $6,710 and ending cash of $90; MD&A contains inconsistent wording for the inception-to-date cash-flow figure.
- Assess the company’s ability to raise capital, repay the demand loan, and continue as a going concern given only $90 in cash and no established revenue source.